Showing results (341-350 of 700) with videos related to
Sort By:
Pageof 70
Cancer|February 14, 2006
Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trialPaul G Richardson, Bart Barlogie, James Berenson, et al.Archives of Dermatology|October 19, 2005
Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantationMartha Q Lacy, William J Hogan, Morie A Gertz, et al.Blood|April 24, 2009
Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health StudyOla Landgren, Robert A Kyle, Jane A Hoppin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2008
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myelomaS Vincent Rajkumar, Laura Rosiñol, Mohamad Hussein, et al.British Journal of Haematology|October 9, 2003
Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myelomaMichael A Thompson, Thomas E Witzig, Shaji Kumar, et al.European Journal of Haematology|May 19, 2010
Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myelomaFrancesca Gay, S Vincent Rajkumar, Patrizia Falco, et al.Clinical Chemistry|December 3, 2014
Monitoring IgA multiple myeloma: immunoglobulin heavy/light chain assaysJerry A Katzmann, Maria A V Willrich, Mindy C Kohlhagen, et al.Leukemia|February 28, 2018
Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosisSurbhi Sidana, Nidhi Tandon, Angela Dispenzieri, et al.Blood Cancer Journal|June 14, 2018
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteriaArjun Lakshman, S Vincent Rajkumar, Francis K Buadi, et al.Blood Cancer Journal|February 27, 2020
Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosisAngela Dispenzieri, Bonnie Arendt, Surendra Dasari, et al.Pageof 70